![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials
The study examined the effects of semaglutide on kidney function and safety in a large, broad type 2 diabetes population. eGFR and UACR were also anal...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Melanocortin 4 receptor (MC4R) receptor plays a part in body weight regulation. Severe early-onset obesity can be caused by biallelic variants in gene...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
EMPA-REG OUTCOME trial was a randomized, double-blind, non-inferiority trial of patients with type 2 diabetes and atherosclerotic cardiovascular disea...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial
The pancreas is small and irregular in shape in people with type 2 diabetes. remission of the disease should restore normal pancreas morphology. This...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial
Testosterone treatment for 2 years reduced the proportion of participants with type 2 diabetes beyond the effects of a lifestyle programme. The treatm...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
The multicentre, double-blind, placebo-controlled, randomized trial was done at 386 study sites in 21 countries. The relative risk reduction for the p...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature
Phaeochromocytoma or paraganglioma in pregnant women can lead to severe complications and death. Unrecognized and untreated PPGL was associated with a...
![](https://umdaa.co/assets/uploads/default/Diabetologist.jpg)
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
SGLT2 inhibitors are a promising treatment option in patients with heart failure. The Empire HF trial is registered with ClinicalTrials.gov and EudraC...